Clinical Trials
3 trialsNCT07459543 2026-03-09
A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
Bristol-Myers Squibb
Phase 4 Not yet recruiting
NCT07369791 2026-01-28
NOBLE
National Health Research Institutes, Taiwan
Phase 2 Not yet recruiting
NCT06683755 2024-11-12
Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
M.D. Anderson Cancer Center
Phase 1/2 Not yet recruiting